614 related articles for article (PubMed ID: 25740538)
1. Immunology of progressive multifocal leukoencephalopathy.
Jelcic I; Jelcic I; Faigle W; Sospedra M; Martin R
J Neurovirol; 2015 Dec; 21(6):614-22. PubMed ID: 25740538
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.
Jelcic I; Jelcic I; Kempf C; Largey F; Planas R; Schippling S; Budka H; Sospedra M; Martin R
Ann Neurol; 2016 Mar; 79(3):404-18. PubMed ID: 26874214
[TBL] [Abstract][Full Text] [Related]
3. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
4. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host.
Hou J; Major EO
J Neurovirol; 2000 May; 6 Suppl 2():S98-S100. PubMed ID: 10871795
[TBL] [Abstract][Full Text] [Related]
7. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.
Bellizzi A; Nardis C; Anzivino E; Rodìo D; Fioriti D; Mischitelli M; Chiarini F; Pietropaolo V
J Neurovirol; 2012 Feb; 18(1):1-11. PubMed ID: 22290500
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
9. Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1.
Chen G; Gorelik L; Simon KJ; Pavlenco A; Cheung A; Brickelmaier M; Chen LL; Jin P; Weinreb PH; Sidhu SS
MAbs; 2015; 7(4):681-92. PubMed ID: 25879139
[TBL] [Abstract][Full Text] [Related]
10. Molecular biology and immunoregulation of human neurotropic JC virus in CNS.
Sweet TM; Del Valle L; Khalili K
J Cell Physiol; 2002 Jun; 191(3):249-56. PubMed ID: 12012320
[TBL] [Abstract][Full Text] [Related]
11. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
13. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
[TBL] [Abstract][Full Text] [Related]
14. New JC virus infection patterns by in situ polymerase chain reaction in brains of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy.
von Einsiedel RW; Samorei IW; Pawlita M; Zwissler B; Deubel M; Vinters HV
J Neurovirol; 2004 Feb; 10(1):1-11. PubMed ID: 14982723
[TBL] [Abstract][Full Text] [Related]
15. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.
Koralnik IJ; Du Pasquier RA; Letvin NL
J Virol; 2001 Apr; 75(7):3483-7. PubMed ID: 11238876
[TBL] [Abstract][Full Text] [Related]
16. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy.
Koralnik IJ
J Neurovirol; 2002 Dec; 8 Suppl 2():59-65. PubMed ID: 12491153
[TBL] [Abstract][Full Text] [Related]
17. Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).
Khalili A; Craigie M; Donadoni M; Sariyer IK
J Neuroimmune Pharmacol; 2019 Dec; 14(4):649-660. PubMed ID: 31452013
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Bauer J; Gold R; Adams O; Lassmann H
Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
[TBL] [Abstract][Full Text] [Related]
19. John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy.
Pietropaolo V; Prezioso C; Bagnato F; Antonelli G
New Microbiol; 2018 Jul; 41(3):179-186. PubMed ID: 29620790
[TBL] [Abstract][Full Text] [Related]
20. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]